Abstract:Background: Therapies targeting immune checkpoint have significantly transformed the treatment of several cancers, including lung cancer. However, only 20% of lung cancer patients show a response to immunotherapies. KRAS and EGFR mutations are significant factors in the development and progression of lung cancer and its response to immunotherapy. Hence, it's vital to understand intra-tumoral heterogeneity, the makeup of the Tumor Microenvironment (TME), and the cellular interactions in tumors with KRAS and EGFR mutations to uncover new insights. Methods: Lung cancer tissues from 200 patients were collected, focusing on KRAS and EGFR mutation statuses, specifically KRAS+/EGFR-, KRAS-/EGFR+, and KRAS-/EGFR-. For each patient, two samples were taken, resulting in a total of 400 tissue microarray (TMA) cores. These samples were imaged at single-cell resolution using the PhenoCycler®-Fusion system, which employed a 42-plex antibody panel targeting immune, tumor, proliferation, and apoptosis markers. The first step in the analysis was cell segmentation, performed using a fine-tuned deep learning model. This process successfully segmented a total of 2.16 million cells across the entire collection of samples. Following this, the protein expressions for each cell were calculated, and unsupervised clustering was performed, resulting in 36 distinct clusters, that were manually annotated into 14 cell phenotypes. The proportions of these cell phenotypes were then quantified for each of the 400 TMA cores and compared across the three mutation groups. The analysis also included the spatial proximity and cellular neighborhoods in relation to these mutation groups. Results: Quantitative analysis focusing on the relative abundance of cell types revealed that the ratio of tumor cells to immune cells was significantly lower in KRAS-/EGFR- tumors compared to those with KRAS+/EGFR- and KRAS-/EGFR+ mutations. Furthermore, the percentages of Regulatory T cells (Tregs) and M1 Macrophages were significantly higher in the KRAS+/EGFR- group compared to the KRAS-/EGFR+ group. Spatial proximity analysis indicated that in the KRAS-/EGFR+ group, M2 Macrophages were significantly closer to Cytotoxic T cells and Helper T cells compared to the distances observed in the other two groups. Moreover, neighborhood analysis identified 20 distinct cellular neighborhoods, each defined by specific cell-cell interactions. COX hazard analysis based on these cellular neighborhoods demonstrated notable variations among the three mutation groups, which are linked to differences in patient outcomes. Conclusions: Through single-cell spatial phenotyping, this work has shown that the spatial immune landscape of lung tumors is influenced by KRAS and EGFR mutation statuses. This presents a novel opportunity to enhance our understanding of the spatial structure of lung cancer and to identify more effective therapeutic targets. Citation Format: Rajender Nandigama, Bassem Ben Cheikh, Ning Ma, Jochen Wilhelm, Laura Klotz, Florian Eichhorn, Mark Kriegsmann, Marek Bartkuhn, Jamal Nabhanizadeh, Sascha Seidel, Thorsten Stiewe, Albrecht Stenzinger, Andreas Weigert, Mario Looso, Friedrich Grimminger, Werner Seeger, Soni Savai Pullamsetti, Niyati Jhaveri, Hauke Winter, Rajkumar Savai. Single-cell spatial landscape of the mutation-specific human lung tumor immune microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5508.

Abstract 605: Single cell RNA sequencing reveals tumor immune microenvironment and T cell receptor diversity in epidermal growth factor receptor (EGFR) mutated lung cancer

Abstract 6829: Identification of immune suppressive features in tumor-associated endothelial cells (TECs) in EGFR-mutant non-small cell lung cancer via single-cell RNA sequencing

Abstract 6868: Exploring myeloid landscapes according to EGFR mutated NSCLC tumor microenvironment

Abstract 5508: Single-cell spatial landscape of the mutation-specific human lung tumor immune microenvironment

Abstract 1989: Intratumor heterogeneity in EGFR-mutant lung tumors mediates targeted therapy resistance and formation of drug tolerant microenvironment

Abstract PR02: Tumor sequestered, neoantigen specific T cells are dynamically increased in circulation following neoadjuvant immunotherapy

Revealing distinct immune landscape in EGFR mutant and EGFR wild type lung adenocarcinoma by using single-cell RNA sequencing.

Abstract 6121: Correlation of tumor immune microenvironment status and driver genes alterations in Chinese non-small-cell lung cancer patients

Abstract 5935: Phenotype profiling of tumor microenvironment in EGFR mutant lung adenocarcinoma with multi-omics data

Abstract 5826: Comprehensive analysis with single-cell RNA sequence and spatial transcriptomics unravels distinctive expression profile of apoptotic-related genes in EGFR-mutated lung cancer

Characteristics of T-Cell Receptor Repertoire and Correlation With EGFR Mutations in All Stages of Lung Cancer

Abstract 2906: Intratumor heterogeneity of non-small-cell lung cancer with EGFR mutations

Abstract 5162: Tumor transcriptional identity as a key predictor of clinical outcome in EGFR-Mutant non-small cell lung cancer

Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma

MA16.06 EGFR Clonality and Tumor Mutation Burden (TMB) by Circulating Tumor DNA (ctdna) Sequencing in Advanced Non-Small Cell Lung Cancer (NSCLC)

EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment

Abstract 1516: Large scale, transcriptome-based analysis of TCR clonality reveals functional immunity in non-small cell lung cancer

Abstract 1609: Inferring the T cell repertoire dynamics in non-small cell lung cancer metastases

Brief Report: The Immune Profiles of the Molecular Subtypes of EGFR-Mutant Lung Adenocarcinomas in a Large Real-World Cohort

Abstract 5853: Regulatory network inference of lung adenocarcinoma drug-tolerant persister cells

A Targetable Egfr-Driven Tumor-Initiating Program In Breast Cancer